Advances and perspectives for antimicrobial peptide and combinatory therapies

Abstract

Antimicrobial peptides (AMPs) have shown cell membrane-directed mechanisms of action. This specificity can be effective against infectious agents that have acquired resistance to conventional drugs. The AMPs’ membrane-specificity and their great potential to combat resistant microbes has brought hope to the medical/therapeutic scene. The high death rate worldwide due to antimicrobial resistance (AMR) has pushed forward the search for new molecules and product developments, mainly antibiotics. In the current scenario, other strategies including the association of two or more drugs have contributed to the treatment of difficult-to-treat infectious diseases, above all, those caused by bacteria. In this context, the synergistic action of AMPs associated with current antibiotic therapy can bring important results for the production of new and effective drugs to overcome AMR. This review presents the advances obtained in the last 5 years in medical/antibiotic therapy, with the use of products based on AMPs, as well as perspectives on the potentialized effects of current drugs combined with AMPs for the treatment of bacterial infectious diseases.

Activatable prodrug for controlled release of an antimicrobial peptide via the proteases overexpressed inCandida albicansandPorphyromonas gingivalis

“…[26,27] However, AMPs can be non-specific and damage host cells. [28,29] Thus, we hypothesized that coatingactivatable systems that are readily dependent on the pathogenesis of the microorganism, would overcome this limitation by retaining the pharmacokinetic properties through selectivity of treatment. This can be achieved through cleavable peptide substrates designed to release the AMP under direct exposure to a pathogenic protease.…”